医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Nanox Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

2020年08月26日 AM01:14
このエントリーをはてなブックマークに追加


 

NEVE ILAN, Israel

NANO-X IMAGING LTD (“Nanox” or the “Company”), an innovative medical imaging technology company, announced today the closing of its initial public offering of 10,555,556 ordinary shares, which includes the full exercise of the underwriters’ option to purchase 1,376,812 additional ordinary shares at a public offering price of US$18.00 per share. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Nanox, were US$190.0 million. All of the shares were offered by Nanox. The shares began trading on the Nasdaq Global Market under the ticker symbol “NNOX” on August 21, 2020.

Cantor Fitzgerald & Co., Oppenheimer & Co. Inc., Berenberg and CIBC Capital Markets acted as joint book-runners. National Securities Corporation acted as co-manager for the offering.

A registration statement, including a prospectus, on Form F-1 relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. The offerings were made only by means of a prospectus. Copies of the final prospectus may be obtained by contacting: Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com, Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York 10004, by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com, Berenberg Capital Markets, LLC, Attention: Equity Capital Markets, 1251 Avenue of the Americas, 53rd Floor, New York, NY 10020, telephone: (646) 949-9000, or CIBC Capital Markets, 425 Lexington Avenue, 5th floor, New York, NY, by telephone at (800) 282-0822, or by email at useprospectus@cibc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200825005756/en/

CONTACT

IR contacts:

Bob Yedid

LifeSci Advisors, LLC

646-597-6989

bob@lifesciadvisors.com

Itzhak Maayan, CFO at Nanox

IR@nanox.vision

Media Contact:

Alona Stein

ReBlonde for Nanox

alona@reblonde.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform